VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Wuliangye Yibin Co., Ltd. vs Amgen Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Wuliangye Yibin Co., Ltd.
000858 · Shenzhen Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Wuliangye Yibin Co., Ltd.'s moat claims, evidence, and risks.
View 000858 analysisAmgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Wuliangye Yibin Co., Ltd. leads (80 / 100 vs 70 / 100 for Amgen Inc.).
- Segment focus: Wuliangye Yibin Co., Ltd. has 3 segments (76.1% in Wuliangye-branded Baijiu products); Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Strong vs Moderate.
- Moat breadth: Wuliangye Yibin Co., Ltd. has 5 moat types across 3 domains; Amgen Inc. has 5 across 3.
Primary market context
Wuliangye Yibin Co., Ltd.
Wuliangye-branded Baijiu products
China baijiu market (sales revenue; producers above designated size)
China
Consumers (premium gifting/banqueting; affluent households)
Branded spirits producer and marketer
76.1%
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
Side-by-side metrics
Moat coverage
Shared moat types
Wuliangye Yibin Co., Ltd. strengths
Amgen Inc. strengths
Segment mix
Wuliangye Yibin Co., Ltd. segments
Full profile >Wuliangye-branded Baijiu products
Oligopoly
Other liquor products (Wuliang NongXiang and other series)
Competitive
Non-liquor products (other)
Competitive
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.